Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06320327 · ClinicalTrials.gov registry record · NA
Topical CBD's Effects on Soreness and Performance
A NA study of Muscle Soreness, sponsored by Joseph Pastina.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06320327: Completed NA study of Muscle Soreness, sponsored by Joseph Pastina.
NCT06320327 is a NA study of Muscle Soreness that has completed, run by Joseph Pastina. The registered enrollment target is 30 participants, roughly in line with the 31-participant average among 4 other Muscle Soreness trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06320327, a NA study of Muscle Soreness, has completed, sponsored by Joseph Pastina.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabidiol (CBD), has been used as a recovery tool for EIMD and DOMS. Despite the rising popularity of CBD products, their effectiveness in mitigating EIMD and DOMS is unknown. Specifically, to the investigators' knowledge, no clinical trials have been completed to assess the effects of topical CBD cream application on soreness, recovery and performance. Therefore, the purpose of the present study was to investigate the effects of CBD cream on DOMS and performance after an intensive lower-body exercise protocol. Specifically, the study's aims were: Aim 1: To assess the effect of topical CBD cream administration on muscle soreness following fatiguing exercise. Hypothesis 1: CBD cream would decrease perceived muscle soreness when compared to a placebo or control (no cream) group. Aim 2: To assess the effect of topical CBD cream administration on muscular performance following fatiguing exercise. Hypothesis 2: Recovery of muscular power would be quicker when CBD cream is applied, compared to a placebo or control (no cream) group. Aim 3: To assess if topical CBD cream has a localized (if any) or systemic effect on muscle soreness. Hypothesis 3: Improvements in muscle soreness would only be observed in localized muscles around where the CBD cream was applied.
Primary Outcome
The vertical jump, or countermovement jump (CMJ), test will utilize the ForceDecks Dual Force Plate System by Vald Performance to measure peak force production and vertical jump height (one plate for each leg; sampling frequency = 1,000 Hz).
Conditions Studied
Interventions
- OTHER Cannabidiol cream
- OTHER Placebo cream
Study Locations (2)
Kentucky
- Seaton Center Building - Lexington
- Multidisciplinary Science Building - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2023-04-30 |
| Phase | NA |
What the finished NCT06320327 record still lists
NCT06320327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, roughly in line with the 31-participant average among 4 other Muscle Soreness trials with a reported enrollment target.
The record links to 1 condition, with Muscle Soreness appearing as the primary indexed condition, and to 2 interventions - of which Cannabidiol cream is the first listed.
NCT06320327 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06320327 about?
NCT06320327 is a clinical study titled "Topical CBD's Effects on Soreness and Performance". Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabi...
What is the current status of trial NCT06320327?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-08-23. Estimated completion is 2023-04-30.
What conditions does trial NCT06320327 study?
This clinical trial studies the following conditions: Muscle Soreness.
What interventions are being tested in trial NCT06320327?
The interventions under investigation include: Cannabidiol cream (OTHER), Placebo cream (OTHER).
Who is sponsoring clinical trial NCT06320327?
This trial is sponsored by Joseph Pastina, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06320327 being conducted?
This trial has 2 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Soreness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI